Cellid, Co., Ltd. (299660.KQ)

KRW 3630.0

(-2.68%)

EBITDA Summary of Cellid, Co., Ltd.

Cellid, Co., Ltd.'s latest annual EBITDA in 2023 was -7.68 Billion KRW , up 0.04% from previous year.
Cellid, Co., Ltd.'s latest quarterly EBITDA in 2024 Q2 was -2.78 Billion KRW , up 20.51% from previous quarter.
Cellid, Co., Ltd. reported an annual EBITDA of -18.63 Billion KRW in 2022, up 36.54% from previous year.
Cellid, Co., Ltd. reported an annual EBITDA of -10.24 Billion KRW in 2021, down -304.65% from previous year.
Cellid, Co., Ltd. reported a quarterly EBITDA of -2.78 Billion KRW for 2024 Q2, up 20.51% from previous quarter.
Cellid, Co., Ltd. reported a quarterly EBITDA of -2.58 Billion KRW for 2023 Q1, down -63.15% from previous quarter.

Annual EBITDA Chart of Cellid, Co., Ltd. (2023 - 2015)

Historical Annual EBITDA of Cellid, Co., Ltd. (2023 - 2015)

Year	EBITDA	EBITDA Growth
2023	-7.68 Billion KRW	0.04%
2022	-18.63 Billion KRW	36.54%
2021	-10.24 Billion KRW	-304.65%
2020	-3.62 Billion KRW	-4.91%
2019	-2.37 Billion KRW	-14.99%
2018	-11.2 Billion KRW	-74.18%
2017	-5.33 Billion KRW	-32.36%
2016	-1.7 Billion KRW	-46.23%
2015	-1.17 Billion KRW	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-1.75 Billion KRW	-434.2%
2024 Q2	-2.78 Billion KRW	20.51%
2023 Q1	-2.58 Billion KRW	-63.15%
2023 FY	- KRW	0.04%
2023 Q4	-2.34 Billion KRW	27.96%
2023 Q3	-3.24 Billion KRW	12.5%
2023 Q2	-3.71 Billion KRW	-43.74%
2022 Q4	-1.58 Billion KRW	70.21%
2022 FY	- KRW	36.54%
2022 Q1	-4.9 Billion KRW	18.4%
2022 Q3	-5.31 Billion KRW	15.49%
2022 Q2	-6.28 Billion KRW	-28.08%
2021 Q3	-4.56 Billion KRW	-1.28%
2021 Q4	-6.01 Billion KRW	-31.86%
2021 Q1	-2.34 Billion KRW	-27.96%
2021 Q2	-4.5 Billion KRW	-91.78%
2021 FY	- KRW	-304.65%
2020 Q4	-1.83 Billion KRW	-50.13%
2020 Q1	-1.38 Billion KRW	-50.99%
2020 Q2	-347.14 Million KRW	75.01%
2020 Q3	-1.22 Billion KRW	-252.21%
2020 FY	- KRW	-4.91%
2019 Q1	-579.09 Million KRW	39.95%
2019 FY	- KRW	-14.99%
2019 Q4	-920.02 Million KRW	-0.83%
2019 Q3	-912.41 Million KRW	9.64%
2019 Q2	-1 Billion KRW	-74.36%
2018 Q2	-326.01 Million KRW	29.7%
2018 FY	- KRW	-74.18%
2018 Q1	-463.72 Million KRW	-49.07%
2018 Q4	-964.39 Million KRW	0.0%
2017 FY	- KRW	-32.36%
2017 Q1	-269.52 Million KRW	0.0%
2017 Q4	-311.07 Million KRW	0.0%
2016 FY	- KRW	-46.23%
2015 FY	- KRW	0.0%

Peer EBITDA Comparison of Cellid, Co., Ltd.

Name	EBITDA	EBITDA Difference
Sam Chun Dang Pharm. Co., Ltd	6.54 Billion KRW	217.327%
Hyundai Bioscience Co., Ltd.	-12.74 Billion KRW	39.732%
ST Pharm Co.,Ltd.	52.48 Billion KRW	114.639%
ABL Bio Inc.	2.1 Billion KRW	465.093%